Clinical trial
Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma
NCT06303583 is registered in ClinicalTrials.gov with Qiu Guoqin as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma
- Lead sponsor
- Qiu Guoqin
- Phase
- Phase 1/2
- Overall status
- Enrolling by invitation
- Start date
- June 1, 2022
- Completion date
- December 31, 2026
- Enrollment
- 30 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.